Elderly patients with resistant hypertension are at increased risk for cardiovascular events. Clinical trials suggest that resistant hypertension involves perhaps 10-15% of hypertension study participants. In this study, 157 resistant hypertension patients older than 60 years were randomized to 8 weeks double-blind treatment with placebo, AML 10 mg/day, OM 40 mg/day and AM x L (10 mg/day) + OM (40 mg/day). Research outcomes suggested that ALM + OM combination therapy had superior efficacy than ALM or OM monotherapies in terms of the clinic blood pressure and 24-h ambulatory blood pressure. In addition, more patients receiving combination therapy (62.5%) achieved BP goal than those treated with placebo (18.4%), AML (37.5) or OM (38.5%) monotherapies. The adverse events in both groups were comparable. Thus, the combination of AML + OM provides a safe and effective option for the treatment of resistant hypertension in challenging elderly patient populations. (C) 2013 Elsevier Ireland Ltd. All rights reserved.